Date: 22nd June, 2026
KMP / Board / Auditor Changes
Not Specified
Dividend Declaration or Non-Declaration
The document discloses that multiple dividends from FY2019 to FY2026 remain unclaimed by certain shareholders:
- Final Dividend for the Year 2018-2019
- Interim Dividend for the Year 2019-2020
- Final Dividend for the Year 2020-2021
- Final Dividend for the Year 2021-2022
- Final Dividend for the Year 2022-2023
- Final Dividend for the Year 2023-2024
- Final Dividend for the Year 2024-2025
- Interim Dividend for the Year 2025-26
Unclaimed dividends prior to these years have already been transferred to IEPF as required under Section 124(5) of the Companies Act, 2013.
Board Meeting Outcomes
Not Specified
Financial Results
Not Specified
Disinvestment / Strategic Actions
Not Specified
Other Operational / Legal / Strategic Disclosures
The disclosure is made pursuant to Regulation 30 read with Schedule III Para A Part A of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and in compliance with Section 124(6) of the Companies Act, 2013 read with Investor Education and Protection Fund Authority (Accounting, Audit, Transfer and Refund) Rules, 2016.
Shares on which dividend has not been encashed or claimed for seven consecutive years or more must be transferred to IEPF. Shareholders have until 16th October, 2026 to claim unpaid dividends. After this date, unclaimed shares will be transferred to IEPF.
Shareholders must contact the Registrar and Transfer Agent (RTA): M/s. MUFG Intime India Pvt. Ltd., Block No. 202, 2nd Floor, Akshay Complex, Near Ganesh Temple, Off. Dhole Patil Road, Pune - 411001, Tel No.: 020 - 26161629, e-mail: investor.helpdesk@in.mpms.mufg.com
Required documentation includes: self-attested KYC documents (PAN, cancelled cheque leaf, latest utility bill as address proof), and details including company name, folio number or DP and Client ID, shareholder name, contact number, and email ID.
After shares are transferred to IEPF, shareholders can claim them by filing eform No. IEPF-5 as prescribed under the Rules.